RxNorm October 2023 Monthly Release

RxNorm October 2023 Monthly Release. NLM Tech Bull. 2023 Sep-Oct;(452):b9.

The RxNorm October 2023 monthly release became available on Monday, October 2, 2023. We have made changes to Xacduro and some tacrolimus products for this release. 

RXNORM DATA CHANGES 

Changes to Xacduro

In response to the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN) feedback regarding issues with antimicrobial use surveillance and the modeling of Xacduro in RxNorm, we have changed Xacduro to a Semantic Branded Drug (SBD) for the RxNorm October 2023 monthly release. The concepts have new RXCUIs shown below.

New modeling:

RXCUI	TTY	STR
2665012	SCD	durlobactam 1000 MG / sulbactam 1000 MG Injection
2665017	SBD	durlobactam 1000 MG / sulbactam 1000 MG Injection [Xacduro]

 

Previous modeling:

RXCUI	TTY	STR
2639100	GPCK	{2 (durlobactam 500 MG Injection) / 1 (sulbactam 1000 MG Injection) } Pack
2639101	BPCK	{2 (durlobactam 500 MG Injection) / 1 (sulbactam 1000 MG Injection) } Pack [Xacduro]

 

Changes to Tacrolimus Products

The Food and Drug Administration (FDA) has changed the therapeutic equivalence rating of some tacrolimus products to BX. Based on feedback from our users, we have created new normal forms for those with the qualitative distinction of BX. 

The new forms are:

RXCUI	TTY	STR
2665161	SCD	BX Rating tacrolimus 0.5 MG Oral Capsule
2665162	SCD	BX Rating tacrolimus 1 MG Oral Capsule
2665163	SCD	BX Rating tacrolimus 5 MG Oral Capsule

The old forms are still available:

RXCUI	TTY	STR
313190	SCD	tacrolimus 0.5 MG Oral Capsule
198377	SCD	tacrolimus 1 MG Oral Capsule
198378	SCD	tacrolimus 5 MG Oral Capsule

For more information about the FDA’s decision see:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-changing-therapeutic-equivalence-rating-accord-healthcare-incs-generics-prograf-tacrolimus-oral.